方法：研究共纳入17例18眼确诊为湿性老年性黄斑变性的患者，给予康柏西普玻璃体腔内注射治疗，初始治疗3mo，每个月给药1次。评估康柏西普玻璃体内注射前后的最佳矫正视力、眼压、散瞳后眼底照相、眼底荧光素血管造影和吲哚菁绿血管造影结果，观察并对比分析治疗前和治疗后1、2、3mo的最佳矫正视力、眼压、黄斑区的渗漏情况以及视网膜黄斑中心凹的厚度。

结果：患者17例18眼接受玻璃体注射康柏西普治疗后3mo随诊时，15眼(83%)的最佳矫正视力不同程度提高，3眼(17%)最佳矫正视力稳定。以Optovue OCT测量18眼治疗前的视网膜黄斑中心凹厚度平均为421.72±54.43μm，治疗后1、2、3mo平均为337.89±25.88、293.56±26.87、266.89±19.10μm，与治疗前相比差异具有统计学意义(P<0.05)。末次随访时，FFA和ICG检查结果显示，15眼(83%)黄斑区渗漏消失，3眼(17%)黄斑区仍存在渗漏，随后再次行康柏西普玻璃体腔内注射1～2次至黄斑区渗漏消失。患者18眼中，有2眼出现了眼压升高(26，23mmHg)，留院观察1d后，眼压恢复至正常水平。1眼接受玻璃体注射后出现球结膜轻度的充血，给予左氧氟沙星滴眼液2d后充血消失。使用该药后未出现与药物相关的严重不良反应。

结论：对于湿性老年性黄斑变性的患者，采用玻璃体腔内注射康柏西普能够有效改善患者的视力，疗效好，见效快，副作用少，安全性也较高。

METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.

RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(P<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions.

CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation.